184 related articles for article (PubMed ID: 9345059)
1. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome.
Tilly H; Gaulard P; Lepage E; Dumontet C; Diebold J; Plantier I; Berger F; Symann M; Petrella T; Lederlin P; Brière J
Blood; 1997 Nov; 90(9):3727-34. PubMed ID: 9345059
[TBL] [Abstract][Full Text] [Related]
2. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
[TBL] [Abstract][Full Text] [Related]
3. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
[TBL] [Abstract][Full Text] [Related]
4. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype.
de Bruin PC; Beljaards RC; van Heerde P; Van Der Valk P; Noorduyn LA; Van Krieken JH; Kluin-Nelemans JC; Willemze R; Meijer CJ
Histopathology; 1993 Aug; 23(2):127-35. PubMed ID: 8406384
[TBL] [Abstract][Full Text] [Related]
5. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
6. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma.
Sandlund JT; Pui CH; Santana VM; Mahmoud H; Roberts WM; Morris S; Raimondi S; Ribeiro R; Crist WM; Lin JS
J Clin Oncol; 1994 May; 12(5):895-8. PubMed ID: 8164039
[TBL] [Abstract][Full Text] [Related]
8. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
9. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features.
Felgar RE; Salhany KE; Macon WR; Pietra GG; Kinney MC
Hum Pathol; 1999 Feb; 30(2):228-36. PubMed ID: 10029454
[TBL] [Abstract][Full Text] [Related]
10. Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas. A clinicopathologic analysis of six cases.
Paulli M; Rosso R; Kindl S; Boveri E; Bonoldi E; Stracca V; Motta T; Arrigoni G; Lazzarino M; Menestrina F
Cancer; 1994 Feb; 73(3):541-9. PubMed ID: 8299075
[TBL] [Abstract][Full Text] [Related]
11. Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity.
Metcalf RA; Bashey S; Wysong A; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2013 Apr; 37(4):617-23. PubMed ID: 23480896
[TBL] [Abstract][Full Text] [Related]
12. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
[TBL] [Abstract][Full Text] [Related]
13. CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: the first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lymphomas.
Tirelli U; Vaccher E; Zagonel V; Talamini R; Bernardi D; Tavio M; Gloghini A; Merola MC; Monfardini S; Carbone A
J Clin Oncol; 1995 Feb; 13(2):373-80. PubMed ID: 7844598
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
16. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.
Cazals-Hatem D; André M; Mounier N; Copin MC; Divine M; Berger F; Bosly A; Kerneis Y; Brière J; Quesnel B; Diebold J; Gaulard P
Am J Surg Pathol; 2001 Mar; 25(3):297-306. PubMed ID: 11224599
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
[TBL] [Abstract][Full Text] [Related]
18. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
19. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
20. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
